

## **Cipla launches Cippioint – a point-of-care device for Non-Communicable Diseases, infectious diseases, and other health conditions**

- Point-of-Care solution to facilitate clinicians in quick and effective decision making
- State-of-the-art device offering a wide range of testing parameters

**Mumbai, India; January 18, 2023:** Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") today announced the launch of Cippioint, a point-of-care testing device. This state-of-the-art device offers a wide range of testing parameters including cardiac markers, diabetes, infectious diseases, fertility, thyroid function, inflammation, metabolic markers, and coagulation markers. The device is CE IVD approved – indicating the device is approved by the European In-Vitro Diagnostic Device Directive, thus ensuring reliable testing solutions.

With entry in these new segments, Cipla has expanded its product offerings for diagnostics laboratories and aims to bridge the current gap in the diagnostic ecosystem in India by providing reliable and accurate tests at affordable prices.

Cippioint – an immunofluorescence based quantitative analyser, will allow healthcare professionals to get test results in 3 to 15 minutes, thus enabling a faster clinical decision-making process. Cippioint has an automated system and user-friendly interface which can be used even in rural areas, mobile vans, and remote areas with limited infrastructure.

Cippioint aims to enable smaller healthcare establishments provide an accurate point-of-care testing experience, ultimately improving patient health outcomes.

Commenting on the launch, **CEO of One India Business, Mr. Achin Gupta** said, "Cipla has always been at the forefront of addressing the global diseases burden. We are actively working towards delivering innovative solutions that enable prompt and effective diagnosis, thereby plugging gaps in the diagnostic ecosystem. This development further strengthens our vision of supporting patients across the healthcare continuum."

### **About Cipla**

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 47 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 86 markets. Cipla is the 3<sup>rd</sup> largest in pharma in India (IQVIA MAT November '22), 3<sup>rd</sup> largest in the pharma private market in South Africa (IQVIA MAT November '22) and is among the most dispensed generic players in the U.S. For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility, and affordability to the centre of the HIV

**Cipla Ltd.**

**Regd. Office** -Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400013, India.

**P** +91 22 24826000 **F** +91 22 24826120 **W** www.cipla.com **E-Mail** contactus@cipla.com **Corporate Identity Number** L24239MH1935PLC002380

movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of "Caring for Life" and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers, and all stakeholders.

For more, please visit [www.cipla.com](http://www.cipla.com), or click on [Twitter](#), [Facebook](#), [LinkedIn](#).